Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Context-Specific Economic Evaluation for Molecular Pathology Tests: An Application in Colorectal Cancer in the West of Scotland.

Bouttell J, Tan YY, Creed D, McGaffin G, Hawkins N, McLaughlin R, Smith G, Westwood P, Williams N, Graham J.

Int J Technol Assess Health Care. 2019;35(4):327-333. doi: 10.1017/S026646231900045X. Epub 2019 Jul 11.

PMID:
31292015
2.

Prenatal exome sequencing analysis in fetal structural anomalies detected by ultrasonography (PAGE): a cohort study.

Lord J, McMullan DJ, Eberhardt RY, Rinck G, Hamilton SJ, Quinlan-Jones E, Prigmore E, Keelagher R, Best SK, Carey GK, Mellis R, Robart S, Berry IR, Chandler KE, Cilliers D, Cresswell L, Edwards SL, Gardiner C, Henderson A, Holden ST, Homfray T, Lester T, Lewis RA, Newbury-Ecob R, Prescott K, Quarrell OW, Ramsden SC, Roberts E, Tapon D, Tooley MJ, Vasudevan PC, Weber AP, Wellesley DG, Westwood P, White H, Parker M, Williams D, Jenkins L, Scott RH, Kilby MD, Chitty LS, Hurles ME, Maher ER; Prenatal Assessment of Genomes and Exomes Consortium.

Lancet. 2019 Feb 23;393(10173):747-757. doi: 10.1016/S0140-6736(18)31940-8. Epub 2019 Jan 31.

3.

Population pharmacokinetic meta-analysis of ramucirumab in cancer patients.

O'Brien L, Westwood P, Gao L, Heathman M.

Br J Clin Pharmacol. 2017 Dec;83(12):2741-2751. doi: 10.1111/bcp.13403. Epub 2017 Sep 27.

4.

A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.

Azaro A, Rodon J, Calles A, Braña I, Hidalgo M, Lopez-Casas PP, Munoz M, Westwood P, Miller J, Moser BA, Ohnmacht U, Bumgardner W, Benhadji KA, Calvo E.

Invest New Drugs. 2015 Jun;33(3):710-9. doi: 10.1007/s10637-015-0241-7. Epub 2015 Apr 24.

PMID:
25902900
5.

A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.

Hollebecque A, Houédé N, Cohen EE, Massard C, Italiano A, Westwood P, Bumgardner W, Miller J, Brail LH, Benhadji KA, Soria JC.

Eur J Cancer. 2014 Mar;50(5):876-84. doi: 10.1016/j.ejca.2013.12.006. Epub 2014 Jan 20.

PMID:
24456794
6.

A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours.

Tolcher A, Goldman J, Patnaik A, Papadopoulos KP, Westwood P, Kelly CS, Bumgardner W, Sams L, Geeganage S, Wang T, Capen AR, Huang J, Joseph S, Miller J, Benhadji KA, Brail LH, Rosen LS.

Eur J Cancer. 2014 Mar;50(5):867-75. doi: 10.1016/j.ejca.2013.11.039. Epub 2014 Jan 15.

PMID:
24440085
7.

PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST.

Hansson EK, Amantea MA, Westwood P, Milligan PA, Houk BE, French J, Karlsson MO, Friberg LE.

CPT Pharmacometrics Syst Pharmacol. 2013 Nov 20;2:e84. doi: 10.1038/psp.2013.61.

8.

Prophylactic ranitidine treatment in critically ill children--a population pharmacokinetic study.

Hawwa AF, Westwood PM, Collier PS, Millership JS, Yakkundi S, Thurley G, Shields MD, Nunn AJ, Halliday HL, McElnay JC.

Br J Clin Pharmacol. 2013 May;75(5):1265-76. doi: 10.1111/j.1365-2125.2012.04473.x.

9.

Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity.

Baugh M, Black D, Westwood P, Kinghorn E, McGregor K, Bruin J, Hamilton W, Dempster M, Claxton C, Cai J, Bennett J, Long C, McKinnon H, Vink P, den Hoed L, Gorecka M, Vora K, Grant E, Percival MD, Boots AM, van Lierop MJ.

J Autoimmun. 2011 May;36(3-4):201-9. doi: 10.1016/j.jaut.2011.01.003. Epub 2011 Mar 24.

PMID:
21439785
10.

Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate.

Ratcliffe P, Adam JM, Baker J, Bursi R, Campbell R, Clark JK, Cottney JE, Deehan M, Easson AM, Ecker D, Edwards D, Epemolu O, Evans L, Fields R, Francis S, Harradine P, Jeremiah F, Kiyoi T, McArthur D, Morrison A, Passier P, Pick J, Schnabel PG, Schulz J, Steinbrede H, Walker G, Westwood P, Wishart G, Udo de Haes J.

Bioorg Med Chem Lett. 2011 Apr 15;21(8):2541-6. doi: 10.1016/j.bmcl.2011.02.023. Epub 2011 Feb 12.

PMID:
21411321
11.

Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.

Ray P, Wright J, Adam J, Boucharens S, Black D, Brown AR, Epemolu O, Fletcher D, Huggett M, Jones P, Laats S, Lyons A, de Man J, Morphy R, Sherborne B, Sherry L, Straten Nv, Westwood P, York M.

Bioorg Med Chem Lett. 2011 Feb 15;21(4):1084-8. doi: 10.1016/j.bmcl.2010.12.104. Epub 2010 Dec 28.

PMID:
21251828
12.

1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitors: separation of desired cellular activity from undesired tissue accumulation through optimization of basic nitrogen pka.

Arbuckle W, Baugh M, Belshaw S, Bennett DJ, Bruin J, Cai J, Cameron KS, Claxton C, Dempster M, Everett K, Fradera X, Hamilton W, Jones PS, Kinghorn E, Long C, Martin I, Robinson J, Westwood P.

Bioorg Med Chem Lett. 2011 Feb 1;21(3):932-5. doi: 10.1016/j.bmcl.2010.12.065. Epub 2010 Dec 19.

PMID:
21227690
13.

Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.

Ray P, Wright J, Adam J, Bennett J, Boucharens S, Black D, Cook A, Brown AR, Epemolu O, Fletcher D, Haunso A, Huggett M, Jones P, Laats S, Lyons A, Mestres J, de Man J, Morphy R, Rankovic Z, Sherborne B, Sherry L, van Straten N, Westwood P, Zaman GZ.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):97-101. doi: 10.1016/j.bmcl.2010.11.060. Epub 2010 Nov 19.

PMID:
21145740
14.

Trifluoromethylphenyl as P2 for ketoamide-based cathepsin S inhibitors.

Cai J, Robinson J, Belshaw S, Everett K, Fradera X, van Zeeland M, van Berkom L, van Rijnsbergen P, Popplestone L, Baugh M, Dempster M, Bruin J, Hamilton W, Kinghorn E, Westwood P, Kerr J, Rankovic Z, Arbuckle W, Bennett DJ, Jones PS, Long C, Martin I, Uitdehaag JC, Meulemans T.

Bioorg Med Chem Lett. 2010 Dec 1;20(23):6890-4. doi: 10.1016/j.bmcl.2010.10.012. Epub 2010 Oct 26.

PMID:
21030256
15.

Optimisation of 2-cyano-pyrimidine inhibitors of cathepsin K: improving selectivity over hERG.

Rankovic Z, Cai J, Kerr J, Fradera X, Robinson J, Mistry A, Finlay W, McGarry G, Andrews F, Caulfield W, Cumming I, Dempster M, Waller J, Arbuckle W, Anderson M, Martin I, Mitchell A, Long C, Baugh M, Westwood P, Kinghorn E, Jones P, Uitdehaag JC, van Zeeland M, Potin D, Saniere L, Fouquet A, Chevallier F, Deronzier H, Dorleans C, Nicolai E.

Bioorg Med Chem Lett. 2010 Nov 1;20(21):6237-41. doi: 10.1016/j.bmcl.2010.08.101. Epub 2010 Aug 24.

PMID:
20843687
16.

6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitors.

Cai J, Baugh M, Black D, Long C, Jonathan Bennett D, Dempster M, Fradera X, Gillespie J, Andrews F, Boucharens S, Bruin J, Cameron KS, Cumming I, Hamilton W, Jones PS, Kaptein A, Kinghorn E, Maidment M, Martin I, Mitchell A, Rankovic Z, Robinson J, Scullion P, Uitdehaag JC, Vink P, Westwood P, van Zeeland M, van Berkom L, Bastiani M, Meulemans T.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4350-4. doi: 10.1016/j.bmcl.2010.06.072. Epub 2010 Jun 17.

PMID:
20598883
17.

4-(3-Trifluoromethylphenyl)-pyrimidine-2-carbonitrile as cathepsin S inhibitors: N3, not N1 is critically important.

Cai J, Fradera X, van Zeeland M, Dempster M, Cameron KS, Bennett DJ, Robinson J, Popplestone L, Baugh M, Westwood P, Bruin J, Hamilton W, Kinghorn E, Long C, Uitdehaag JC.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4507-10. doi: 10.1016/j.bmcl.2010.06.043. Epub 2010 Jun 10.

PMID:
20580231
18.

Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors.

Rankovic Z, Cai J, Kerr J, Fradera X, Robinson J, Mistry A, Hamilton E, McGarry G, Andrews F, Caulfield W, Cumming I, Dempster M, Waller J, Scullion P, Martin I, Mitchell A, Long C, Baugh M, Westwood P, Kinghorn E, Bruin J, Hamilton W, Uitdehaag J, van Zeeland M, Potin D, Saniere L, Fouquet A, Chevallier F, Deronzier H, Dorleans C, Nicolai E.

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1524-7. doi: 10.1016/j.bmcl.2010.01.100. Epub 2010 Jan 25.

PMID:
20149657
19.

Allosteric modulation of the cannabinoid CB1 receptor.

Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, McLean A, McIntosh L, Goodwin G, Walker G, Westwood P, Marrs J, Thomson F, Cowley P, Christopoulos A, Pertwee RG, Ross RA.

Mol Pharmacol. 2005 Nov;68(5):1484-95. Epub 2005 Aug 19.

PMID:
16113085
20.

Fission yeast Cdc37 is required for multiple cell cycle functions.

Westwood PK, Martin IV, Fantes PA.

Mol Genet Genomics. 2004 Feb;271(1):82-90. Epub 2003 Dec 3.

PMID:
14652737
21.

Long-term effects of Class III treatment with rapid maxillary expansion and facemask therapy followed by fixed appliances.

Westwood PV, McNamara JA Jr, Baccetti T, Franchi L, Sarver DM.

Am J Orthod Dentofacial Orthop. 2003 Mar;123(3):306-20.

PMID:
12637903
22.

Rat brain p64H1, expression of a new member of the p64 chloride channel protein family in endoplasmic reticulum.

Duncan RR, Westwood PK, Boyd A, Ashley RH.

J Biol Chem. 1997 Sep 19;272(38):23880-6.

23.

Arterial gas embolism following a 1-meter ascent during helicopter escape training: a case report.

Benton PJ, Woodfine JD, Westwood PR.

Aviat Space Environ Med. 1996 Jan;67(1):63-4.

PMID:
8929206
24.

Stiff upper lip? You can stoic it.

Westwood P.

Nurs Stand. 1993 Dec 1;8(11):42.

PMID:
27665910
25.

A kinematic analysis of recovery of the ability to stand up following stroke.

Ada L, Westwood P.

Aust J Physiother. 1992;38(2):135-42. doi: 10.1016/S0004-9514(14)60558-4.

26.

Medical audit: a Well Woman Clinic in the Royal Naval training practice, Gibraltar.

Westwood PR.

J R Nav Med Serv. 1991 Spring;77(1):49-53.

PMID:
1941763
27.

Screening of vasectomy specimens.

Westwood PJ, Hunt AC.

J Clin Pathol. 1973 Sep;26(9):723-4. No abstract available.

Supplemental Content

Loading ...
Support Center